Heron Therapeutics Q4 revenue dips as Acute Care segment holds fort

Heron Therapeutics

26/02/2026 13:10

Overview

Biotechnology firm's Q4 2025 net revenue was $40.6 mln, slightly down yr/yr

Acute Care franchise revenue grew 57.3% yr/yr in Q4 2025

Company projects 2026 net revenue of $173 to $183 mln

Outlook

Heron expects 2026 net revenue between $173 mln and $183 mln

Company forecasts 2026 adjusted EBITDA between $10 mln and $20 mln

Heron cites improved reimbursement clarity as a factor for 2026 revenue growth

Result Drivers

ZYNRELEF ADOPTION - Enhanced distributor incentives and CMS approval of a product-specific J-Code accelerated ZYNRELEF adoption

APONVIE UTILIZATION - Inclusion in guidelines and dedicated sales team boosted APONVIE utilization

ACUTE CARE GROWTH - Strategic decisions led to 65% yr/yr net revenue growth in Acute Care franchise

Company press release: ID:nGNX6GzT8R

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Product Sales
$40.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Heron Therapeutics Inc is $4.00, about 270.4% above its February 25 closing price of $1.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)